Cabot-Wellington’s AbbVie ABBV Stock Holding History

Cabot-Wellington’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-40,000	Closed	-$3.71M	–	10
2018 Q2	$3.71M	Buy	+40,000	New	+$3.91M	2.54%	5
2015 Q4	–	Sell	-172,663	Closed	-$9.39M	–	28
2015 Q3	$9.39M	Sell	172,663 -2,073	-1%	-$135K	5.65%	7
2015 Q2	$11.7M	Sell	174,736 -1,427	-0.8%	-$93.2K	5.79%	6
2015 Q1	$10.3M	Sell	176,163 -5,473	-3%	-$331K	4.38%	11
2014 Q4	$11.9M	Sell	181,636 -2,075	-1%	-$131K	4.42%	11
2014 Q3	$10.6M	Sell	183,711 -725	-0.4%	-$40.3K	3.94%	12
2014 Q2	$10.4M	Buy	184,436 +1,248	+0.7%	+$65.5K	3.68%	13
2014 Q1	$9.42M	Buy	183,188 +27,098	+17%	+$1.37M	3.51%	14
2013 Q4	$8.24M	Hold	156,090	–	–	3.03%	15
2013 Q3	$6.98M	Buy	156,090 +2,745	+2%	+$122K	2.73%	15
2013 Q2	$6.34M	Buy	+153,345	New	+$6.71M	2.66%	15

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cabot-Wellington's ABBV Position: Q3 2018 in Review

Cabot-Wellington sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 40,000 shares — an estimated $3.71M sold.

Cabot-Wellington first reported a position in ABBV in Q2 2013 and held it in 11 quarters. The position peaked at $11.9M in Q4 2014. 1,957 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

Cabot-Wellington reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
Cabot-Wellington sold 40,000 AbbVie shares in Q3 2018, an estimated $3.71M.
Cabot-Wellington first reported a position in AbbVie in Q2 2013 and held it in 11 quarters.
Cabot-Wellington's AbbVie position peaked at $11.9M in Q4 2014.
1,957 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on Cabot-Wellington's 13F filing for Q3 2018, filed 17 Oct 2018.